Dalfampridine ( DrugBank: Dalfampridine )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
4	原発性側索硬化症	1
13	多発性硬化症／視神経脊髄炎	10

4. 原発性側索硬化症

臨床試験数 : 5 / 薬物数 : 13 - (DrugBank : 6) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 25

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02868567 (ClinicalTrials.gov)	March 2016	17/3/2016	Use of Dalfampridine in Primary Lateral Sclerosis	A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridinein Primary Lateral Scler ...	Motor Neuron Disease, Upper	Drug: dalfampridine	Hospital for Special Surgery, New York	NULL	Active, not recruiting	18 Years	99 Years	All	35	Phase 1	United States

First Previous1Next Last

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05730738 (ClinicalTrials.gov)	June 1, 2021	5/12/2021	Dalfampridine in Egyptian Patients With Multiple Sclerosis	Effect of Dalfampridineon Gait Impairment, Cognition and Fatigue in Egyptian Patients With Multiple ...	Multiple Sclerosis	Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release;Drug: Placebo	Ain Shams University	NULL	Recruiting	18 Years	N/A	All	100	N/A	Egypt
2	EUCTR2014-003498-41-AT (EUCTR)	22/09/2015	06/08/2015	Effects of dalfampridine on mobility in the context of daily life	Effects of dalfampridineon mobility in the context of daily life - Fampridine Study in Activities of ...	Motor behaviour and cognition in multiple sclerosis patients;Therapeutic area: Diseases [C] - Nervou ...	Trade Name: Fampyra INN or Proposed INN: FAMPRIDINE	Medical University of Vienna	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Austria
3	NCT02391961 (ClinicalTrials.gov)	April 1, 2015	3/3/2015	Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis	Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis	Multiple Sclerosis;Internuclear Ophthalmoplegia;Fatigue	Drug: Dalfampridine;Drug: Placebo	VA Office of Research and Development	NULL	Completed	18 Years	65 Years	All	23	Phase 2	United States
4	NCT02259361 (ClinicalTrials.gov)	November 2014	1/10/2014	Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS	Efficacy of Sustained-release Oral Dalfampridineon Upper Extremity Function in Patients With Multipl ...	Multiple Sclerosis	Drug: Sustained-release oral dalfampridine;Drug: Placebo	Sheba Medical Center	NULL	Not yet recruiting	18 Years	70 Years	Both	30	Phase 4	Israel
5	NCT02166346 (ClinicalTrials.gov)	February 2014	16/6/2014	Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)	Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dal ...	Transverse Myelitis;Neuromyelitis Optica;Idiopathic Transverse Myelitis;Myelitis NOS	Drug: Dalfampridine;Drug: Placebo	Johns Hopkins University	Acorda Therapeutics	Completed	18 Years	70 Years	All	24	Phase 2	United States
6	NCT02006160 (ClinicalTrials.gov)	December 2011	6/6/2012	Effects of Dalfampridine on Cognition in Multiple Sclerosis	Effects of Dalfampridine on Cognition in Multiple Sclerosis	Multiple Sclerosis	Drug: dalfampridine;Drug: placebo	State University of New York at Buffalo	NULL	Completed	18 Years	60 Years	All	61	Phase 2/Phase 3	United States
7	NCT01444300 (ClinicalTrials.gov)	September 2011	20/9/2011	Dalfampridine for Imbalance in Multiple Sclerosis	Dalfampridine to Improve Imbalance in Multiple Sclerosis: A Pilot Study	Multiple Sclerosis;Fatigue	Drug: Dalfampridine;Drug: Placebo	Oregon Health and Science University	Acorda Therapeutics	Completed	20 Years	59 Years	All	24	Phase 2	United States
8	NCT01337986 (ClinicalTrials.gov)	May 2011	13/4/2011	Ampyra for Optic Neuritis in Multiple Sclerosis	Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis	Multiple Sclerosis;Optic Neuritis	Drug: Dalfampridine/Placebo;Drug: Placebo/Dalfampridine	Washington University School of Medicine	Acorda Therapeutics	Completed	18 Years	55 Years	All	53	Phase 2/Phase 3	United States
9	NCT01328379 (ClinicalTrials.gov)	March 2011	29/3/2011	Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis	Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Do ...	Multiple Sclerosis	Drug: Dalfampridine-ER 5mg;Drug: Dalfampridine-ER 10mg;Other: Placebo	Acorda Therapeutics	NULL	Completed	18 Years	70 Years	All	430	Phase 3	United States
10	NCT01356940 (ClinicalTrials.gov)	November 2010	18/5/2011	A Placebo Controlled Trial of DalfampridineER for Ambulatory Activity in People With Multiple Sclero ...	A Randomized Controlled Double-blind Cross-over Trial of DalfampridineER for Effect on Ambulatory Ac ...	Multiple Sclerosis	Drug: dalfampridine ER;Drug: placebo	Brown, Theodore R., M.D., MPH	Acorda Therapeutics	Completed	18 Years	75 Years	All	43	Phase 4	United States

First Previous1Next Last

先頭へ